Lhasa Limited shared knowledge shared progress

Archive

This is a library of Lhasa's blog articles. 

  • A day in the life of a Junior Software Developer   Fabrizio   V2
    less than 10 minutes

    A day in the life of a Junior Software Developer at Lhasa Limited

    Hello, my name is Fabrizio Campo.

    I work in the Software Delivery department at Lhasa Limited, as a Junior Software Developer. 

    Here is my typical day as a Junior Software Developer at Lhasa Limited.

    20 June 2022

  • 5 things you should know about the data in the Lhasa Carcinogenicity Database (LCDB)
    Clock: 5 minutes5 minutes

    5 things you should know about the data in the Lhasa Carcinogenicity Database (LCDB)

    Would your toxicology assessments benefit from free access to long-term carcinogenicity study data? The Lhasa Carcinogenicity Database (LCDB) is a widely used, free resource of long-term carcinogenicity study data.

    In this article we explore 5 things you should know about the data in the LCDB.

    25 May 2022

  • Expert review blog
    Clock: less than 5 minutesless than 5 minutes

    Is expert review an essential step when assessing mutagenic potential of drug impurities?

    A provision for the application of ‘expert knowledge’ is mentioned within the ICH M7 guideline. However, as (Q)SAR models continue to be updated and their predictive performance and structural coverage improves, this raises the question of whether expert review is still necessary… 

    05 May 2022

  • Controlling potentially mutagenic impurities – 8 top tips from industry experts
    Clock: less than 5 minutesless than 5 minutes

    Controlling potentially mutagenic impurities – 8 top tips from industry experts

    A key consideration within drug substance synthesis is the potential presence of mutagenic impurities. Potentially mutagenic impurities (PMIs) often arise from reagents which are essential for the synthesis of a final active pharmaceutical ingredient (API) meaning that the risk is therefore often unavoidable. As a result, there is a need to assess the risk posed by mutagenic impurities.
    To discuss this topic in more detail, we were delighted to welcome Andrew Teasdale PhD and Muzaffar Khan PhD, to present at our webinar; Controlling potentially mutagenic impurities - hear from industry experts!

    In case you missed this event, we have summarised the top eight take away tips from the webinar, for quick and easy consumption within this article. 

    04 April 2022

  • Replace reduce refine
    Clock: less than 5 minutesless than 5 minutes

    Replace, Reduce, Refine - How Lhasa Limited are supporting the 3Rs

    Last year, a revolutionary guideline on Defined Approaches for Skin Sensitisation (OECD GL No.497) was released by the OECD. It is the first ever guideline that recommends the use of a combination of non-animal methods to predict whether a chemical can cause skin allergies. Since the publication of this guideline, Lhasa Limited have developed ‘Skin Sensitisation Defined Approach ITSv1 1.0’ – a web application containing one of the defined approaches published by the OECD, which provides hazard and potency skin sensitisation predictions without the use of animal tests. This tool is a step towards full replacement of animal testing for skin sensitisation and employs the 3Rs principle.

    02 March 2022

  • Picture of blue pills, tablets, caplets
    Clock: 5 minutes5 minutes

    Nitrites in Excipients Data Sharing Consortium: Supporting Nitrosamine Risk Assessment

    Nitrite analysis of excipients is a new and analytically challenging area, with many organisations working quickly to determine the best practice and techniques to use.

    The Nitrites in Excipients data sharing consortium was established in September 2020 and is part of Lhasa Limited's effort to support the global challenge of nitrosamine risk assessment.

    22 February 2022

  • A day in the life of an Application Scientist at Lhasa Limited
    less than 10 minutes

    A day in the life of a Senior Application Scientist at Lhasa Limited

    Hi, I’m Jess and I work in Lhasa’s Applied Sciences team.

    My role as an Application Scientist requires me to have comprehensive knowledge about many different products and processes. One day I could be dealing with complex software based queries from one of our members, the next I could be discussing a very specific scientific principle. It’s certainly a learning curve, but very rewarding!

    31 January 2022

  • Reflecting on 2021 and planning 2022Our CEO, Dr Chris Barber reflects on a successful 12 months for Lhasa and discusses our plans for the year ahead.
    Clock: 5 minutes5 minutes

    Reflecting on 2021 and planning 2022

    Our CEO, Dr Chris Barber reflects on a successful 12 months for Lhasa and discusses our plans for the year ahead.

    20 January 2022

  • Predicting N-nitrosamine carcinogenic potency using structure-activity relationships (SARs)
    Clock: less than 5 minutesless than 5 minutes

    Predicting N-nitrosamine carcinogenic potency using structure-activity relationships (SARs)

    This blog article introduces an insightful publication by Lhasa Principal Scientist, Dr. David Ponting and Dr. Kevin Cross from Instem, which investigates whether improvements in structure-activity relationships can more accurately predict N-nitrosamine carcinogenic potency.

    17 December 2021

  • How Derek Nexus and Sarah Nexus meet the 5 OECD principles
    Clock: less than 5 minutesless than 5 minutes

    How Derek Nexus and Sarah Nexus meet the 5 OECD principles

    In this article, we discuss how Derek Nexus and Sarah Nexus meet the 5 OECD principles.

    30 November 2021

© 2022 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.